Chardan Starts Opexa Therapeutics (OPXA) at Buy Following Efficacy Data for Tovaxin
Tweet
Share
E-mailGet Alerts OPXA Hot Sheet
Price: $0.97 --0%
Rating Summary:
1 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Rating Summary:
1 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Join SI Premium – FREE
An analyst at Chardan Capital initiated coverage on Opexa Therapeutics (NASDAQ: OPXA) with a Buy rating and a $2.20 price target.
Shares of Opexa are sharply higher Friday following data from this morning on the company's tovaxin. The stock last traded at $2.01, up 9.8 percent from Thursday's closing price.
Chardan's new price target represents potential upside of about 9.5 percent from where the stock is currently trading.
For more ratings news on Opexa Therapeutics click here and for the rating history of Opexa Therapeutics click here.
Shares of Opexa are sharply higher Friday following data from this morning on the company's tovaxin. The stock last traded at $2.01, up 9.8 percent from Thursday's closing price.
Chardan's new price target represents potential upside of about 9.5 percent from where the stock is currently trading.
For more ratings news on Opexa Therapeutics click here and for the rating history of Opexa Therapeutics click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lake Street Capital Markets Starts Research Solutions Inc. (RSSS) at Buy
- CapitalOne Starts Heron Therapeutics (HRTX) at Overweight
- JPMorgan Starts COSCO SHIPPING Energy Transportation (1138:HK) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
